

FORM P-29C (REV 11-98)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371

BMID9814US

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR

09/786040

INTERNATIONAL APPLICATION NO.
PCT/EP99/06321INTERNATIONAL FILING DATE
27 August 1999 (27.08.99)PRIORITY DATE CLAIMED
1 September 1998 (01.09.98)

TITLE OF INVENTION

HUMAN MONOCLONAL ANTIBODIES TO THE ISLET CELL ANTIGEN IA-2

APPLICANT(S) FOR DO/EO/US

ENDL, Josef; WILD, Thomas; BERLO, Suzanne Elisabeth; and LITTY, Verena

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371 (c) (2))
 - a. ☒ is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ has been transmitted by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☒ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. ☒ A copy of the International Search Report (PCT/ISA/210).
8. ☐ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
 - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ have been transmitted by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☐ have not been made and will not be made.
9. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
10. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)). (unexecuted)
11. ☒ A copy of the International Preliminary Examination Report (PCT/IPEA/409).
12. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).

Items 13 to 20 below concern document(s) or information included:

13. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
14. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
15. ☒ A **FIRST** preliminary amendment. (to follow)
16. ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
17. ☐ A substitute specification.
18. ☐ A change of power of attorney and/or address letter.
19. ☒ Certificate of Mailing by Express Mail
20. ☒ Other items or information:

General Appointment of Representative for U.S. Patent and Trademark Office Matters (1pp).

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR

097786040

INTERNATIONAL APPLICATION NO

PCT/EP99/06321

ATTORNEY'S DOCKET NUMBER

BMID9814US

21. The following fees are submitted:

BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) :

- ☐ Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO \$970.00
- ☒ International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$840.00
- ☐ International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$690.00
- ☐ International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$670.00
- ☐ International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4) \$96.00

ENTER APPROPRIATE BASIC FEE AMOUNT =**\$860.00**

Surcharge of **\$130.00** for furnishing the oath or declaration later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492 (e)).

\$0.00

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE
Total claims	- 20 =	0	x \$18.00
Independent claims	- 3 =	0	x \$78.00
Multiple Dependent Claims (check if applicable).			<input type="checkbox"/>

\$0.00**TOTAL OF ABOVE CALCULATIONS =****\$860.00**

Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28) (check if applicable).

☐**\$0.00****SUBTOTAL =****\$860.00**

Processing fee of **\$130.00** for furnishing the English translation later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492 (f)).

+

\$0.00**TOTAL NATIONAL FEE =****\$860.00**

Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable).

☐**\$0.00****TOTAL FEES ENCLOSED =****\$860.00**

Amount to be:
refunded \$
charged \$

- ☐ A check in the amount of _____ to cover the above fees is enclosed.
- ☒ Please charge my Deposit Account No. **50-0877** in the amount of **\$860.00** to cover the above fees.
A duplicate copy of this sheet is enclosed.
- ☒ The Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment to Deposit Account No. **50-0877**. A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Marilyn L. Amick
Roche Diagnostics Corporation
9115 Hague Road, Bldg. D
P.O. Box 50457
Indianapolis, IN 46250-0457
Telephone No. (317) 521-7561
Facsimile No. (317) 521-2883

Marilyn Amick
SIGNATURE

Marilyn L. Amick

NAME

30,444

REGISTRATION NUMBER

28 February 2001

DATE



Docket No. BMID 9814US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: ENDL, Josef, et al.

Application No.: 09/786,040

Group No.: To Be Assigned

Filed: February 28, 2001

Examiner: To Be Assigned

For: HUMAN MONOCLONAL ANTIBODIES TO THE ISLET CELL ANTIGEN IA-2

Box SN

Assistant Commissioner for Patents

Washington, D.C. 20231

**STATEMENT TO SUPPORT FILING AND SUBMISSION
IN ACCORDANCE WITH 37 C.F.R. §§ 1.821-1.825**

Dear Sir:

The undersigned hereby states that the content of the Sequence Listing filed herewith (1 page) and the computer readable copy of the Sequence Listing, submitted in accordance with 37 C.F.R. § 1.821(c) and (e), respectively, are the same.

Applicants believe there is no fee associated with this Submission. However, the Examiner is hereby authorized to charge any fees associated with this paper to Deposit Account No. 50-0877. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

Marilyn L. Amick, Reg. No. 30,444
Roche Diagnostics Corporation
9115 Hague Road, Bldg. D
P.O. Box 50457
Indianapolis, IN 46250-0457
Telephone No.: (317) 521-7561
Facsimile No.: (317) 521-2883

Date: June 15, 2001

CERTIFICATION UNDER 37 C.F.R. 1.8

I hereby certify that this document is being deposited on JUNE 15, 2001 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the: Box SN, Assistant Commissioner for Patents, Washington, D.C. 20231.

Leah Robison

09/786040
PTO/PCT Rec'd 17 JUL 2001

Docket No. BMID9814US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: ENDL, Josef, *et al.*

Application No.: 09/786,040

Group No.: To Be Assigned

Filed: February 28, 2001

Examiner: To Be Assigned

For: HUMAN MONOCLONAL ANTIBODIES TO THE ISLET CELL ANTIGEN IA-2

Assistant Commissioner for Patents
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Sir:

Please enter the following amendments prior to examination of the above-referenced application:

IN THE CLAIMS:

Please cancel claims 1 to 15, without prejudice, in the originally filed application.

Please enter new claims 16 to 27, clean copies of which are shown on the attached pages as required by 37 C.F.R. 1.121. Because the previous claims have been canceled, no marked up copies of the previous claims are enclosed herein.

Respectfully submitted,



Date: July 17, 2001

Marilyn L. Amick, Reg. No. 30,444
Roche Diagnostics Corporation
9115 Hague Road, Bldg. D
P.O. Box 50457
Indianapolis, IN 46250-0457
Telephone No.: (317) 521-7561
Facsimile No.: (317) 521-2883

09/786040-07101

BMID 9814

What is claimed is:

16. Cell line IA-2, 96-3-1, deposit number DSM ACC2365, producing a monoclonal antibody binding specifically to the cytoplasmic domain IA-2ic of human islet cell antigen IA-2.
17. A monoclonal antibody produced from cell line IA-2, 96-3-1, deposit number DSM ACC2365, said antibody binding specifically to the cytoplasmic domain IA-2ic of islet cell antigen IA-2.
18. A monoclonal antibody that binds specifically to islet cell antigen IA-2 in a manner equivalent to that of an antibody from cell line IA-2, 96-3-1, deposit number DSM ACC2365.
19. The antibody of claim 18, wherein said antibody belongs to the immunoglobulin class IgG.
20. The antibody of claim 19, wherein said antibody belongs to the immunoglobulin subclass IgG1.
21. A method for producing a monoclonal antibody that binds specifically to islet cell antigen IA-2, said method comprising:
 - (a) isolating peripheral mononuclear cells (PBMNC) from the blood of a donor having a high serum antibody titre to IA-2,

BMID 9814

- (b) enriching the relevant B cell subpopulation from step (a) by isolating membrane IgG-positive B cells,
 - (c) immortalizing the isolated membrane IgG-positive B cell subpopulation from step (b),
 - (d) culturing the immortalized cells from step (c) and testing for the presence antibody that binds specifically to islet cell antigen IA-2 in the culture supernatant,
 - (e) cloning cells from step (d) which produce antibody that binds specifically to islet cell antigen IA-2 in the presence of feeder cells which contain no cytotoxic T lymphocytes, and
 - (f) isolating antibody that binds specifically to islet cell antigen IA-2.
22. A method for detecting an antibody that binds specifically to islet cell antigen IA-2 or IA-2ic in a sample suspected of containing said antibody, said method comprising:
- (a) contacting said sample with a binding partner comprising an IA-2 or IA-2ic antigen, thereby forming an immune complex, said binding partner bound directly or indirectly to a solid phase,
 - (b) determining said antibody by contacting said immune complex with a receptor comprising a complex of an antibody that binds specifically to islet cell antigen IA-2ic and a detectable label,

BMID 9814

- (c) detecting the presence or amount of said label as a measure of said antibody in said sample.
23. The method of claim 22 wherein the antibody comprising said complex comprising said receptor binds specifically to islet cell antigen IA-2 in a manner equivalent to that of an antibody from cell line IA-2, 96-3-1, deposit number DSM ACC2365.
24. A method for isolating an islet cell antigen IA-2 from a sample suspected of containing said antigen, said method comprising:
- (a) contacting said sample with a monoclonal antibody that specifically binds to IA-2, said antibody bound directly or indirectly to a solid phase, thereby forming an immune complex,
 - (b) separating the immune complex from the solid phase, and
 - (c) cleaving the immune complex and isolating said antigen.
25. The method of claim 24 wherein said antibody binds specifically to islet cell antigen IA-2 in a manner equivalent to that of an antibody from cell line IA-2, 96-3-1, deposit number DSM ACC2365.
26. A method for producing an anti-idiotypic antibody directed against an antibody binding specifically to the cytoplasmic domain IA-2ic of human islet cell antigen IA-2 comprising:

BMID 9814

- (a) immunizing an animal with an antibody binding specifically to the cytoplasmic domain IA-2ic of human islet cell antigen IA-2,
 - (b) immortalizing spleen cells from said immunized animal,
 - (c) culturing the immortalized cells from step (b) and testing for the presence of anti-idiotypic antibody directed against an antibody binding specifically to the cytoplasmic domain IA-2ic of human islet cell antigen IA-2 in the culture supernatant,
 - (d) cloning cells from step (c) which produce anti-idiotypic antibody directed against an antibody binding specifically to the cytoplasmic domain IA-2ic of human islet cell antigen IA-2, and
 - (e) isolating anti-idiotypic antibody directed against an antibody binding specifically to the cytoplasmic domain IA-2ic of human islet cell antigen IA-2.
27. The method of claim 26 wherein said antibody binding specifically to the cytoplasmic domain IA-2ic of human islet cell antigen IA-2 binds specifically to islet cell antigen IA-2 in a manner equivalent to that of an antibody from cell line IA-2, 96-3-1, deposit number DSM ACC2365.

Human monoclonal antibodies to the islet cell antigen IA-2

The invention concerns human monoclonal antibodies to the islet cell antigen IA-2, a process for their production, the use of human monoclonal antibodies in a method for detecting antibodies to IA-2, a method for detecting antibodies to the islet cell antigen IA-2 and a method for detecting IA-2.

Type I insulin-dependent diabetes mellitus (IDDM) is due to an autoimmune destruction of the insulin-producing β cells of the pancreas. The development of autoantibodies to β cell antigens precedes the development of a clinically diagnosable diabetes. These autoantibodies are sensitive markers for identifying the preclinical phase of the disease. Antibodies that react with the β cells in the islets of Langerhans are also frequently found in newly diagnosed diabetic patients. The autoantibodies as a whole are also referred to as islet cell antibodies (ICA).

ICA are sensitive and specific markers for the prognosis and diagnosis of human IDDM. Previously characterized islet cell antigens to which autoantibodies are formed include insulin (Palmer et al. 1983, Science 222, 1337-1339), glutamate decarboxylase (GAD, Bækkeskov et al. 1990, Nature 347, 151-156), carboxypeptidase H (Castano et al. 1991, J. Clin. Endocrinol. Metab. 73, 1197-1201) islet cell antigen ICA 69 (Pietropaolo et al. 1993, J. Clin. Invest. 92, 359-371) and the antigen IA-2 which is also referred to as ICA512 (Solimena et al. 1996, EMBO

09/786040 04404

J. 15, 2102-2114).

Up to now it has not been possible to clarify whether autoantibodies that are directed towards β cell antigens contribute directly to the development of the disease or whether the occurrence of the autoantibodies is a phenomenon that occurs after the destruction of the β cells.

However, according to present knowledge the occurrence of autoantibodies correlates with the development of diabetes.

It has been shown that especially autoantibodies to IA-2 occur in most of the newly diagnosed IDDM patients and that the IA-2-specific autoantibodies are associated with a rapid progression of the diabetes disease. In addition IA-2-specific autoantibodies appear to be more specific for IDDM than GAD autoantibodies and moreover occur less frequently in other autoimmune diseases without IDDM (Roll and Ziegler 1997, Exp. Clin. Endocrinol. Diabetes 105, 1-14).

The autoantigen IA-2 is a transmembrane protein that has a segment that crosses the membrane and a cytoplasmic domain (IA-2ic) which contains the epitopes for antibody binding (Solimena et al. 1996, EMBO J. 15, 2102-2114). IA-2 is an intrinsic membrane protein of secretory vesicles that is expressed in peptide secreting endocrine cells and in neurones which contain neurosecretory vesicles. IA-2 has a significant homology to IA-2 β which is also known as phogrin. IA-2 β is a transmembrane protein like IA-2, but unlike IA-2 it is primarily expressed in β cells. IA-2 β and IA-2 are

proteins of the receptor type and both belong to the class of protein tyrosine phosphatases (Roll and Ziegler 1997, supra).

In the prior art ICA (islet cell antibodies) are determined for the detection of IDDM by measurements on pancreatic tissue sections using indirect immunofluorescence. In this method the autoantibodies in the sample to be examined that bind to the islet cell structures are detected by fluorescent-labelled antibodies that are specific for human IgG. However, these ICA measurements are technically very complicated and difficult to standardize since the results obtained with different pancreatic tissues from different donors varies greatly.

In the prior art autoantibodies to IA-2 and GAD are also determined by simple radioligand binding assays in serum samples. These assays use in vitro translated, radioactively labelled antigens (Dittler, J. et al 1998, Diabetes 47, 592-597). In order to prepare radioactively labelled antigens, the cDNA of the respective antigen is transcribed in vitro using a rabbit reticulocyte lysate. The mRNA is then translated in the presence of radioactively labelled amino acids (usually labelled with ³⁵S, sulphur-35). Binding of the autoantibodies to the labelled antigen is detected by means of the radioactive signal of the labelled antigen after separation of the antigen-antibody complex from the free antigen by for example filtration or solid phase binding.

Although these detection methods can be partially automated, they have the major disadvantage that one has

09786040.074704

to work with radioactivity which requires laborious and expensive precautionary measures. The labelling efficiencies for the antigen that can be achieved by in vitro translation vary greatly from batch to batch. In addition the labelled antigens have a very short shelf-life due to radiolysis and the short half-life of sulphur-35.

A diagnostic test for the direct detection of IA-2-specific autoantibodies that can be carried out simply, rapidly and in an automated manner has previously not been described in the prior art. This is in particular due to the fact that standardized IA-2-specific autoantibodies have previously not been available. Hitherto only high-titre sera from IDDM patients were used as a standard or calibration material. The disadvantage of this material is that such serum is not available in an unlimited amount and thus batch and patient-dependent variations in the antibody content of the respective standard sera occur. Hence there is no comparability between experimental results from different laboratories.

The object was therefore to provide human monoclonal antibodies which specifically recognize the islet cell antigen IA-2 and to provide a diagnostic test procedure for the quantitative detection of the IA-2-specific autoantibodies by means of a standard curve which at least partially overcomes the disadvantages of the prior art.

The object is achieved by human monoclonal antibodies which specifically react with islet cell antigen IA-2. These for example include the antibodies which are

09785040 "074701

produced by the cell line IA-2, 96-3-1, deposited at the DSMZ ("Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH", Braunschweig, Germany) on 13.08.1998 under the number DSM ACC2365.

The invention therefore concerns human monoclonal antibodies to the islet cell antigen IA-2. These antibodies are preferably of the IgG isotype, particularly preferably of the IgG1 isotype.

It is known in the prior art that human autoantibodies can be produced against the islet cell antigen GAD (glutamate decarboxylase) (EP-A-0 499 176). The described method comprises the following steps:

Immortalizing human lymphocytes of prediabetics or diabetics, treating the culture supernatant of the immortalized cells (by EBV transformation) with a conjugate of antibodies to human Fcγ and a label, subsequent treatment with human immunoglobulin, incubation with immobilized human pancreatic islet cells or immobilized GAD, identification of an immortalized human cell culture which produces an antibody to pancreatic islet cells by determining the label bound to the immobilized islet cells or to the immobilized GAD, isolation of a human immortalized cell which produces this antibody, proliferation of this immortalized cell and isolation of the monoclonal antibody produced by these cells.

However, the method described in EP-A-0 499 176 does not allow the production of human monoclonal antibodies to IA-2. The first difficulty already becomes apparent in the selection of the donor lymphocytes. It is not

09786040 "074704

possible to use any donor lymphocytes, but rather the lymphocytes must be derived from selective prediabetics or diabetics with high IA-2-specific serum antibody titres.

The antibody titres are determined by a radioligand binding assay. In this assay the DNA coding for IA-2 is transcribed in vitro by a reticulocyte lysate and translated in the presence of ³⁵S-methionine. Subsequently a few microlitres (2 - 5 µl have proven to be suitable) patient serum is incubated with the radioactively labelled IA-2 and the immune complexes are separated from free antigen over protein-A Sepharose. The radioactivity bound to the protein-A Sepharose is determined in a scintillation counter. The measured cpm are converted into arbitrary units by means of a selected high titre patient serum. For example it was defined that 1000 cpm corresponds to 100 U in the patient serum used in this study. This patient serum is used as an arbitrary standard for the determinations. Only lymphocytes whose donors had a titre of more than 80 U were used for the transformations since IA-2-positive primary cultures were only discovered for these donors.

Moreover it proved to be advantageous to carry out a preselection for IgG-producing B lymphocytes. In peripheral blood there are ca. 10 times more IgM-producing B lymphocytes than IgG-producing B cells. On the other hand the relevant autoantibodies to IA-2 are of the IgG subtype (Zhang et al, 1997, Diabetes 46, 40-43). The relevant B cell subpopulation can be enriched 10-fold by isolating the membrane IgG-positive B lymphocytes. These are isolated by labelling the human B lymphocytes with an antibody from the mouse that is

specific for human IgG and subsequently binding magnetic beads that are coated with sheep anti-mouse IgG. The labelled cells can be positively selected from the cell suspension by applying a magnet.

Furthermore problems occurred in the culture of the immortalized lymphocytes since the immortalized IA-2-specific B cells only had a low proliferation rate and were frequently overgrown by unspecific but rapidly growing immortalized B cells. It turned out that the proliferation of the immortalized IA-2-specific B cell lines can be greatly improved by adding growth factors such as IL-6 or IL-10. An additional problem was that the immortalized B cell lines secrete factors which adversely affect the growth of the cell lines. These factors include above all TGF-beta, IF-gamma and TNF-alpha. Removal of these inhibitory factors by frequently changing the culture medium results in a higher transformation rate and a more rapid growth of the EBV-transformed B cell lines.

A crucial factor for successful cloning (see below) of the resulting EBV-transformed B lymphocytes is to introduce limiting amounts of B lymphocytes into the individual wells (wells of the microtitre plate) right from the beginning. The prior art recommends several thousand purified peripheral mononuclear cells per well (Peyron, E. et al. 1994, J. Immunology 153, 1333-1339; Madec. A.- M. et al 1996, J. Immunology 156, 3541-3549). It surprisingly turned out that no more than 400 IgG-positive cells/well can be used for the primary transformation. The transformation rate is about 1 out of 80 B cells, i.e. a maximum of 5 different clones grow per well. This increases the probability that one can isolate the relevant clones in the subsequent single

cell cloning in which only a few EBV-transformed B cell clones grow (often only 1-2 %). It is also surprising that most of the positive primary wells can be isolated at an even lower seeding density which can be interpreted to mean that already too many clones are formed with 400 B cells per well and consequently clones that grow more slowly are suppressed by rapidly growing cells.

After a growth period of ca. 2 weeks the culture supernatants of the primary cell cultures are then tested for the production of IA-2-specific antibodies for example by means of an ELISA test on immobilized IA-2. Screening for IA-2-specific antibodies by means of the cytoplasmic domain of IA-2 which is also referred to as IA-2ic has proven to be particularly suitable according to the invention.

So-called feeder cells have to be added in the subsequent single cell cloning for the stabilization of the cell lines since EBV-transformed B cell lines cannot survive at a low cell density (< 25 per well). Autologous (derived from the same donor) or allogenic (derived from a different donor) peripheral blood lymphocytes irradiated with 4000 rad are used as feeder cells.

The cloning efficiency can be decisively improved by removing cytotoxic T lymphocytes (CD8-positive cells) from the feeder cell population. The CD8 cells are preferably removed by immunomagnetic separation. For this the peripheral blood lymphocytes are for example incubated with magnetic microbeads to which monoclonal antibodies to the human CD8 antigen are coupled. The

09785040-04701

labelled cells are removed by applying a magnet, the remaining cells are irradiated and used at a concentration of 20,000 - 50,000 per well.

It has also proven to be advantageous for the production of the antibodies according to the invention to carry out a quality check of the feeder cells. It was found that the growth-promoting function of these feeder cells varies greatly from donor to donor. The feeder cells of some donors even had an inhibitory effect on growth. Hence a major improvement was to firstly examine each new batch of feeder cells on an established monoclonal EBHV-transformed B cell line (MICA 5) as a test cell line for their suitability for the cloning procedure and to sort out "harmful" feeder batches. For this purpose single cell clonings of MICA 5 were carried out on irradiated blood lymphocytes from different donors. The cloning efficiency was determined after ca. 3 weeks by microscopic determination of the number of growth wells. Only those feeder cells were used which enabled a cloning efficiency of at least 20 %.

The immortalization step can be carried out by transformation with EBV (Epstein Barr virus) known to a person skilled in the art. This transformation is preferred according to the invention. The most frequently described method in the literature for EBV transformation (see Ifversen, P. et al 1993, Hum. Antibod. Hybridomas 4, 115-123) is to incubate B lymphocytes with EBV for 2-3 hours to allow virus uptake. Afterwards the cells are washed to remove the virus. However, it was surprisingly found that the transformation rate could be increased by not washing out the virus but instead to incubate it together with the B cells during the entire incubation period up to

the first change of medium (after ca. 7 days).

However, the immortalization can also be carried out by fusion with suitable myeloma cells. It is also conceivable that the monoclonal antibodies to IA-2 — according to the invention could be produced by the so-called phage display method (Nissim, A. et al. 1994, EMBO J. 13, 3, 692-698). In this method the mRNA is isolated directly from the lymphocytes of the IDDM patients. The immunoglobulin genes can be amplified (for example by means of the polymerase chain reaction) from the cDNA prepared in this manner. The genes produced in this manner can in turn be expressed in a phage library as Fab or single chain Fv from which the phages binding to IA-2 can be isolated.

It was not possible to produce human monoclonal antibodies to the islet cell antigen IA-2 until the difficulties described above had been overcome.

Hence a preferred subject matter of the invention are monoclonal antibodies which are produced by the cell line IA-2, 96-3-1, deposited on 13.08.1998 at the DSMZ ("Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH", Braunschweig, Germany) under the number DSM ACC2365. The cell line DSM ACC2365 is also a subject matter of the invention.

Antibodies are also a subject matter of the invention which can bind to IA-2 in an equivalent manner to those produced by the cell line IA-2, 96-3-1 (DSM ACC2365). The term "can bind in an equivalent manner" refers to antibodies in which there is a detectable epitope overlap with the defined known antibody. This epitope

09785040-074701

overlap can be easily detected with the aid of a competitive test system. For example an enzyme immunoassay is used to examine the extent to which an antibody competes with the known antibody for binding to a defined antigen or to a defined epitope (for example IA-2ic). For this immobilized IA-2ic antigen is for example incubated with the known monoclonal antibody which carries a label and with an excess of the antibody under examination. It can then be easily determined to what extent the examined antibody can displace the defined antibody from binding to the antigen by detection of the bound label. If there is a displacement of at least 50 % with a 10^5 -fold excess, then an epitope overlap is present.

The invention additionally concerns human monoclonal antibodies to the islet cell antigen IA-2 which can be obtained by the process steps of immortalizing human lymphocytes from prediabetics or diabetics with high serum antibody titres (> 80 U) to IA-2, culturing the immortalized lymphocytes with growth factors while simultaneously removing inhibitory factors by frequently changing the medium, detecting the IA-2-specific human monoclonal antibodies in the culture supernatant preferably by means of ELISA, cloning the human immortalized cell line which produces this antibody in the presence of feeder cells which contain no cytotoxic T lymphocytes, proliferating this immortalized cell optionally with the addition of growth factors, and isolating the monoclonal antibody produced by this clone.

The invention also concerns a process for the production of human monoclonal antibodies which specifically react with the islet cell antigen IA-2 comprising the steps

immortalizing human lymphocytes from prediabetics or diabetics with high serum antibody titres (> 80 U/ml) to IA-2, culturing the immortalized lymphocytes with growth factors while simultaneously removing inhibitory factors by frequently changing the medium, detecting the IA-2-specific human monoclonal antibodies in the culture supernatant preferably by means of ELISA, cloning the human immortalized cell line which produces this antibody in the presence of feeder cells which contain no cytotoxic T lymphocytes, proliferating this immortalized cell optionally with the addition of growth factors, and isolating the monoclonal antibody produced by this clone.

The individual steps of the process are carried out as described in the previous sections.

The term "monoclonal antibody" in the sense of the invention is understood to include all antibody fragments in addition to the intact immunoglobulins. These for example include Fab, Fab' or F(ab)'₂ fragments. If the term "antibody" is not supplemented by the words "monoclonal" or "polyclonal", then it means both types of antibodies i.e. chimeric constructs and all fragments listed above.

The IA-2-specific monoclonal antibodies according to the invention react specifically with IA-2 and they preferably react with the cytoplasmic part of IA-2 the so-called IA-2ic. Hence the invention also concerns antibodies to IA-2 which react specifically with the cytoplasmic part of IA-2 the so-called IA-2ic. The process steps described above are used analogously to produce these antibodies.

09785040-074701

An ELISA test is preferably used to identify the IA-2-specific monoclonal antibodies. At least 1000 primary wells have to be tested for each donor in order to find anti-IA-2-specific EBV-transformed B cell lines. Such an extensive screening cannot be carried out with the very laborious RIA of the prior art. The very high sample throughput can only be achieved by developing an ELISA. This semiautomatic ELISA enables several thousand culture supernatants to be tested per day and hence allows the discovery of the very seldom event of an IA-2-positive primary well.

In the ELISA the streptavidin-coated microtitre plates are coated with IA-2-biotin or IA-2ic-biotin. Subsequently the coated plates are incubated with various dilution steps of human sera from prediabetics or established diabetics. Defined amounts of a purified human IA-2-specific antibody are incubated concurrently on the same microtitre plate. Afterwards the plates are washed and a peroxidase-labelled sheep anti-human-Fcγ-specific antibody conjugate is added to detect bound anti-IA-2 antibodies. Bound IA-2-specific antibodies are detected by a colour reaction with ABTS[®] (azino-di-[3-ethylbenzthiazoline sulfonate (6)], catalogue No. 756 407, Boehringer Mannheim GmbH Germany). The content of anti-IA-2 antibodies in patient sera can be deduced from the absorbances of the standard curve taking into consideration the dilution factor.

In order to prepare the antigen IA-2ic which is used in the ELISA, the IA-2ic gene was amplified from an islet cell-specific cDNA using the following primers which have been published by Payton et al. (1995) in J. Clin. Invest. 96, 1506-1511:

09785040, 074704

5'-ATGCAGCAAGACAACGAGCGCCTG-3' and
5'-TCACTGGGGCAGGGCCTTGAG-3'

The amplification products were cloned into a pin point vector and expressed in E. coli as soluble, biotinylated fusion protein. The fusion protein was purified on monomeric avidin-Sepharose. The biotinylated IA-2ic was bound to streptavidin-coated microtitre plates, incubated with the IA-2-specific monoclonal antibodies according to the invention and bound antibody was detected by a peroxidase-labelled anti-human IgG conjugate. In order to exclude the possibility that the antibodies were directed against the biotinylated amino-terminal domain of the fusion protein, the biotin binding domain of the fusion protein (Tag protein) was also expressed alone and tested in the ELISA. The IA-2-specific antibodies did not recognize the Tag protein. The IA-2-specific antibodies were also tested in a RIA. For this the DNA for IA-2ic was transcribed and translated in vitro in the presence of ³⁵S-methionine, incubated with the IA-2-specific antibodies and the immune complexes were immobilized by adding protein A Sepharose. The radioactivity in the immunoprecipitates was determined by liquid scintillation counting.

The present invention also includes a method for detecting human antibodies or autoantibodies to the islet cell antigen IA-2 in a sample. All formats familiar to a person skilled in the art come into consideration as test formats and an indirect ELISA test is preferred. It has proven to be suitable to contact purified native or recombinant IA-2 antigen or IA-2ic antigen with the sample such that the sample antibodies can bind specifically to the antigen. If the antigen is provided with a group that can bind to a solid phase

such as biotin, then the immune complex can be subsequently immobilized on a streptavidin-coated solid phase. The antigen can also already be directly or indirectly bound to the solid phase when it is incubated with the sample. After separation of the solid from the liquid phase the sample antibodies are preferably detected by binding a labelled antibody which is directed against the Fc part of human antibodies, generally the Fc part of human IgG and subsequently measuring the label. All labels familiar to a person skilled in the art can be used as the label, for example enzymes such as peroxidase, haptens such as digoxigenin, fluorescent dyes or substances capable of electrochemiluminescence or chemiluminescence.

A competitive test format is also conceivable in which the IA-2 or IA-2ic antigen is bound directly or indirectly to a solid phase and a defined concentration of a labelled inventive human monoclonal antibody to IA-2 or IA-2ic is added as a receptor and incubated with the antigen. If the sample is added simultaneously or subsequently, the sample antibodies and labelled receptor antibodies compete with one another for binding to the antigen. After separating the solid from the liquid phase, the label is determined in one or both phases. A low signal of the label on the solid phase indicates a high concentration of sample antibodies.

Comparison of the resulting sample measurements with measured values for a series of standards that have been previously determined, enable quantification of the sample antibodies. Defined concentrations of the inventive monoclonal antibodies to IA-2 or IA-2ic are used in such a series of standards.

All body fluids familiar to a person skilled in the art can be used as samples for detecting antibodies to IA-2. These for example include whole blood, serum or plasma, urine and saliva.

A further subject matter of the invention is the use of a human monoclonal antibody to IA-2 or IA-2ic as a standard or as a receptor in a method for determining antibodies to an islet cell antigen, preferably to the islet cell antigen IA-2.

A further subject matter of the invention is the use of a human monoclonal antibody to the islet cell antigen IA-2 for isolating the islet cell antigen IA-2. In order to isolate the islet cell antigen IA-2, the inventive antibodies can be coupled to a solid phase by methods known to a person skilled in the art.

Subsequently the sample containing IA-2 is incubated with the antibodies bound to the solid phase and the other components are separated. Cleavage of the immune complex between the antibody and antigen for example by a high salt concentration and subsequent elution enable the antigen to be obtained in a pure form.

The invention also concerns anti-idiotypic antibodies whose antigen binding site corresponds to the structure of the antigen IA-2 or IA-2ic. Such an anti-idiotypic antibody can be obtained by immunization with a human antibody to IA-2 according to the invention, immortalizing the spleen cells of the immunized animals, cloning those immortalized cells which produce antibodies that bind to the binding region of the IA-2-specific antibodies and isolating the antibodies

09786040-034704

produced by these clones by known methods.

Another subject matter of the invention is a method for detecting IA-2 in a sample which is characterized in that at least one monoclonal antibody according to the invention is used for this as the binding partner. The test is preferably carried out as a sandwich ELISA. An antibody to IA-2 which can be an antibody according to the invention is used as a binding partner for this which is bound to a solid phase by methods known to a person skilled in the art (for example via biotin/streptavidin). The IA-2 present in the sample binds to the antibody that is bound to the solid phase. The bound IA-2 is detected by means of a further binding partner which carries a label. The further binding partner is also preferably an antibody and also binds specifically to IA-2 but recognizes a different epitope to that recognized by the binding partner that is bound to the solid phase. The labelled binding partner can be a monoclonal antibody according to the invention if the antibody bound to the solid phase recognizes another epitope. All labels familiar to a person skilled in the art can be used as the label. These for example include enzymes such as peroxidase, haptens such as digoxigenin, fluorescent dyes or substances capable of electro-chemiluminescence or chemiluminescence.

The invention is further elucidated by the following examples.

09785040-074701

Example 1:

Selection of donors for the isolation of B lymphocytes

In order to increase the probability of a successful transformation of anti-IA-2-specific B lymphocytes from peripheral blood, donors were selected for the lymphocyte isolation which had a high serum antibody titre against IA-2.

The antibodies were determined by an in vitro translation assay (see Zhang et al. 1997, Diabetes 46, 40-43 and Dittler J. et al 1998, Diabetes 47, 592-597). Blood was withdrawn from newly diagnosed diabetics and serum was obtained by known methods. A volume of 2-5 μ l of the individual sera was incubated overnight at 4°C with the IA-2ic polypeptide that was radioactively labelled (ca. 15,000 cpm) by in vitro translation in 50 μ l precipitation buffer (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 % Triton X-100, 0.1 % aprotinin) while rotating. Subsequently 50 μ l of a 50 % protein A-Sepharose suspension was added and it was incubated for a further hour. Afterwards it was washed three times with the incubation buffer and the radioactivity of the beads was determined in a liquid scintillation instrument. A high titre diabetic serum which produced ca. 1000 cpm in the immunoprecipitate for a serum quantity of 5 μ l was used as an arbitrary standard. This value was defined as being equivalent to 100 U. On this basis the normal sera had levels of ca. 5 U. Only lymphocytes from patients whose sera had a titre of more than 80 U were used for the subsequent transformation of the peripheral blood lymphocytes.

Example 2:

Cell separation and EBV-transformation

Only those lymphocyte donors whose sera had a titre of at least 80 U were used to isolate B lymphocytes. 20 - 50 ml blood was collected from these donors and used to isolate the peripheral mononuclear cells (PBMNC) by means of density gradient centrifugation.

The classical tests for detecting IA-2-specific serum antibodies use protein A-Sepharose to separate the immune complexes. Hence it must be assumed that the anti-IA-2 antibodies are almost exclusively of the IgG immunoglobulin class (Zhang et al., Diabetes, 1997, 46, 40-43 and Dittler J. et al. Diabetes, 1998, 47, 592-597). However, since the B lymphocytes of peripheral blood produce predominantly IgM, the membrane IgG-positive B cells were isolated in order to enrich the relevant B cell subpopulation. For this the PBMNC were adjusted to a concentration of 3×10^6 cells/ml with ice cold IMDM/10 % foetal calf serum (IMDM/10 % FCS). Subsequently an anti human-IgG antibody from the mouse was added at a concentration of 10 μ g/ml. The cells were then rolled for 30 minutes at 4°C to prevent the cells from sedimenting during the incubation. They were subsequently centrifuged at 200*g for 10 minutes at room temperature, the supernatant was aspirated and the cells were washed twice with IMDM/10 % FCS.

Afterwards the cells were taken up in IMDM/10 % FCS at a concentration of 1×10^7 cells/ml (total cell count ca. 1×10^7 cells) and incubated with Magnetobeads (Dynal M-280) which had been coated with sheep anti-mouse IgG.

Approximately 10 beads per target cell were added (it was assumed that about 5 % of the PBMNC express membrane IgG).

The cells were rolled with the beads for 30 minutes at 4°C. Afterwards the reaction vessel was placed for 5 minutes in the magnetic holder in order to separate the labelled cells. The supernatant was aspirated, the beads were resuspended in 1 ml medium and again placed for 5 minutes in the magnetic holder. The supernatant was again aspirated, the tube was removed from the magnetic holder and the isolated cells were resuspended in 0.5 ml IMDM/10 % FCS.

Subsequently 2 ml concentrated Epstein-Barr virus suspension was added. The virus suspension was obtained from the supernatant of a confluent culture of the B 95-8 marmoset cell line (ATCC CRL 1612). The B cells were incubated for 2 hours in an incubator at 37°C, 7 % CO₂ for the virus absorption. The tube was moved several times during the incubation phase in order to prevent cell sedimentation.

Afterwards a serial dilution of the separated B cells was made such that 100, 200 and 400 B cells were present in 100 µl IMDM/10 % FCS. Then allogenic PBMNC (without CD8-positive cells) that had been irradiated with 4000 rad were added to these cell suspensions as feeder cells (50,000 feeder cells per 150 µl cell suspension). Subsequently 100 U/ml IL-6 was added. 150 µl cell suspension per well was aliquoted into 96-well round bottom plates and incubated for 2 weeks at 5 % CO₂ and 37°C. The medium was changed after 7-10 days.

09786040-074704

Example 3:

Screening assay for EBV-transformed B cell lines that produce IA-2 antibodies

After 2 weeks the culture supernatants of the EBV lines were tested in an ELISA for reactivity to recombinant IA-2. The intracellular part of IA-2 (IA-2ic) was expressed as the antigen in *Escherichia coli* in combination with a biotin-labelled peptide at the NH₂ terminus. The fusion protein was purified by affinity chromatography on a streptavidin column.

Streptavidin coated microtitre plates were coated for one hour at room temperature with IA-2ic biotin at a concentration of 100 ng/ml. Subsequently the plates were washed with 0.15 mol/l NaCl/0.05 % Tween 20. 50 µl RPMI/10 % FCS was added first to the plates and subsequently 50 µl culture supernatant of the EBV-transformed B cells was added. It was incubated for 1 hour at room temperature while shaking. Afterwards the plates were washed and 100 µl of a peroxidase-labelled sheep anti-human Fcγ antibody (Boehringer Mannheim GmbH, catalogue No. 1089 196, 100 mU/ml in PBS/0.5 % bovine serum albumin) was added to detect bound anti-IA-2 antibodies. Subsequently it was again incubated for 1 hour at room temperature while shaking. Excess conjugate was removed by washing three times with 0.15 mol/l NaCl/0.05 % Tween 20. Subsequently 100 µl ABTS® (1 mg/ml, Boehringer Mannheim GmbH, catalogue No. 756 407) in 40 mmol/l citrate buffer pH 4.4 containing 3.25 mmol/l sodium perborate was added and the absorbance was measured at 405 nm after incubating for 45 minutes at room temperature while shaking.

In a typical transformation mixture $2-5 \times 10^5$ membrane IgG-positive B cells were isolated from initially 1×10^7 PBMNC. These were divided into ca. 1000 wells. The number of wells that were identified as positive in the screening test was in the range between 1 and 3 wells per 1000 tested wells. The absorbance of the positive wells was in the range 1500-2000 mA.

Example 4:

Cloning EBV-transformed B cell lines

Those EBV-transformed B cell lines whose culture supernatant reacted positive in the ELISA were cloned. For this the cells were deposited singly into 96-well microtitre plates with the aid of a fluorescence-activated cell sorter and irradiated CD8-depleted PBMNC (5×10^4 cells/well, 4000 rad) were added. The cloning medium was composed of IMDM/10 % FCS/100 U/ml IL-6. The culture supernatants containing growing clones were tested by means of ELISA and the positive clones were expanded. Mass culture for isolating antibodies was carried out in a Tecno mouse bioreactor. The antibodies were isolated from the supernatant by ammonium sulfate precipitation and chromatography over protein A or protein G Sepharose.

09785040-074704

Claims

1. Human monoclonal antibodies which react specifically with the islet cell antigen IA-2.
2. Human monoclonal antibodies as claimed in claim 1, wherein they react specifically with IA-2ic, the cytoplasmic part of IA-2.
3. Human monoclonal antibodies as claimed in claim 1 or 2, which can be obtained by the process steps of immortalizing human lymphocytes from prediabetics or diabetics with high serum antibody titres to IA-2, culturing the immortalized lymphocytes with growth factors while simultaneously removing inhibitory factors, detecting the IA-2-specific human monoclonal antibodies in the culture supernatant, cloning the human immortalized cell line which produces this antibody in the presence of feeder cells which contain no cytotoxic T lymphocytes, proliferating this immortalized cell optionally with the addition of growth factors, and isolating the monoclonal antibody produced by this clone.
4. Human monoclonal antibodies as claimed in one of the claims 1 to 3, wherein they belong to the IgG class.
5. Human monoclonal antibodies as claimed in claim 4, wherein they belong to the subclass IgG1.

6. Human monoclonal antibodies as claimed in claims 1 to 5, wherein they can be obtained from the cell line IA-2, 96-3-1 with the depositary number DSM ACC2365.
7. Human monoclonal antibodies as claimed in claims 1 to 6, which can bind to IA-2 in an equivalent manner to the antibodies that are produced by the cell line IA-2, 96-3-1, depositary number DSM ACC2365.
8. Cell line IA-2, 96-3-1 with the depositary number DSM ACC2365.
9. Process for producing human monoclonal antibodies as claimed in one of the claims 1 to 7 comprising the steps immortalizing human lymphocytes from prediabetics or diabetics with high serum antibody titres to IA-2, culturing the immortalized lymphocytes with growth factors while simultaneously removing inhibitory factors, detecting the IA-2-specific human monoclonal antibodies in the culture supernatant, cloning the human immortalized cell line which produces this antibody in the presence of feeder cells which contain no cytotoxic T lymphocytes, proliferating this immortalized cell optionally with the addition of growth factors and isolating the monoclonal antibody produced by this clone.
10. Use of a human monoclonal antibody as claimed in one of the claims 1 to 7 as a standard in a method for determining antibodies to an islet cell antigen.

09785040-074704

11. Use of a human monoclonal antibody as claimed in one of the claims 1 to 7 as a receptor in a method for determining antibodies to an islet cell antigen.
12. Use of a human monoclonal antibody as claimed in one of the claims 1 to 7 for isolating the islet cell antigen IA-2.
13. Method for detecting antibodies to the islet cell antigen IA-2 in a sample, wherein a monoclonal antibody as claimed in one of the claims 1 to 7 is used as a standard.
14. Anti-idiotypic antibody which is directed against antibodies that react with the islet cell antigen IA-2 which can be obtained by immunization with an antibody as claimed in one of the claims 1 to 7, immortalizing the spleen cells of the immunized animals, cloning those immortalized cells which produce antibodies that bind to antibodies against IA-2 and isolating the antibodies produced by these clones by known methods.
15. Method for detecting the islet cell antigen IA-2 in a sample, wherein at least one monoclonal antibody as claimed in one of the claims 1 to 7 is used as the binding partner.

Docket No.
BMID9814US

Declaration and Power of Attorney For Patent Application

English Language Declaration

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

HUMAN MONOCLONAL ANTIBODIES TO THE ISLET CELL ANTIGEN IA-2

the specification of which

(check one)

☐ is attached hereto.

☒ was filed on February 28, 2001 as United States Application No. or PCT International Application Number 09/786,040 and was amended on _____

(if applicable)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) or Section 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate or PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)

Priority Not Claimed

PCT/EP99/06321
(Number)
198 39 736.4

PCT
(Country)
Germany

27 August 1999
(Day/Month/Year Filed)
1 September 1998

☐

☐

(Number)

(Country)

(Day/Month/Year Filed)

☐

(Number)

(Country)

(Day/Month/Year Filed)

I hereby claim the benefit under 35 U.S.C. Section 119(e) of any United States provisional application(s) listed below:

_____ (Application Serial No.)	_____ (Filing Date)
_____ (Application Serial No.)	_____ (Filing Date)
_____ (Application Serial No.)	_____ (Filing Date)

I hereby claim the benefit under 35 U. S. C. Section 120 of any United States application(s), or Section 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. Section 112, I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, C. F. R., Section 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application:

_____ (Application Serial No.)	_____ (Filing Date)	_____ (Status) (patented, pending, abandoned)
_____ (Application Serial No.)	_____ (Filing Date)	_____ (Status) (patented, pending, abandoned)
_____ (Application Serial No.)	_____ (Filing Date)	_____ (Status) (patented, pending, abandoned)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. (list name and registration number)

Marilyn L. Amick, Reg. No. 30,444
 D. Michael Young, Reg. No. 33,819
 Brent A. Harris, Reg. No. 39,215
 Richard T. Knauer, Reg. No. 35,575
 Kenneth J. Waite, Reg. No. 45,189
 Michelle Neff, Reg. No. 47,817
 Jill Lynn Woodburn, Reg. No. 39,874

Send Correspondence to: Marilyn L. Amick
Roche Diagnostics Corporation
9115 Hague Road, Bldg. D, P.O. Box 50457
Indianapolis, IN 46250-0457

Direct Telephone Calls to: (name and telephone number)
Marilyn L. Amick, Telephone No. (317) 521-7561

Full name of sole or first inventor <u>ENDL, Josef</u>	
Sole or first inventor's signature <u>Josef Endl</u>	Date <u>05/21/01</u>
Residence <u>Ulmenstrasse 12, D-82362 Weilheim, Germany</u> DEX	
Citizenship <u>German</u>	
Post Office Address (same as residence address)	

Full name of second inventor, if any <u>WILD, Thomas</u>	
Second inventor's signature <u>Thomas Wild</u>	Date <u>05/23/01</u>
Residence <u>Ludwig-März-Str. 2, 82377 Penzberg</u> <u>Trifhofstrasse 23, D-82362 Weilheim, Germany</u> DEX	
Citizenship <u>Austrian</u>	
Post Office Address (same as residence address)	

340

Full name of third inventor, if any BERLO, Suzanne Elisabeth	
Third inventor's signature <i>S. E. Berlo</i>	Date <i>18 June 2001</i>
Residence Burg v/d Oeverstrasse 26, NL-5076 GL Haaren, Netherlands <i>DLX</i>	
Citizenship Dutch	
Post Office Address (same as residence address)	

400

Full name of fourth inventor, if any LITTY, Verena	
Fourth inventor's signature <i>Verena Litty</i>	Date <i>10.06.01</i>
Residence Landwehrstrasse 32e, D-80336 Munich, Germany <i>DLX</i> <i>Karlstr. 1e 82152 Planegg</i>	
Citizenship German	
Post Office Address (same as residence address)	

Full name of fifth inventor, if any	
Fifth inventor's signature	Date
Residence	
Citizenship	
Post Office Address	

Full name of sixth inventor, if any	
Sixth inventor's signature	Date
Residence	
Citizenship	
Post Office Address	



BMID 9814.ST25
SEQUENCE LISTING

<110> Wild, Thomas
Litty, Verena
Endl, Josef
Berlo, Suzanne Elisabeth

<120> Human monoclonal antibodies against islet cell antigen IA-2

<130> BMID 9814 US

<140> US 09/786,040

<141> 2001-02-28

<150> DE 19839736.4

<151> 1998-09-01

<150> PCT/EP99/06321

<151> 1999-08-27

<160> 2

<170> PatentIn version 3.1

<210> 1

<211> 24

<212> DNA

<213> Unknown

<220>

<223> Primer

<400> 1

atgcagcaag acaacgagcg cctg
24

<210> 2

<211> 21

<212> DNA

<213> Unknown

<220>

<223> Primer

<400> 2

tcactggggc agggccttga g
21